Literature DB >> 22415637

Serial correlation in optimal design for nonlinear mixed effects models.

Joakim Nyberg1, Richard Höglund, Martin Bergstrand, Mats O Karlsson, Andrew C Hooker.   

Abstract

In population modeling two sources of variability are commonly included; inter individual variability and residual variability. Rich sampling optimal design (more samples than model parameters) using these models will often result in a sampling schedule where some measurements are taken at exactly the same time point, thereby maximizing the signal-to-noise ratio. This behavior is a result of not appropriately taking into account error generation mechanisms and is often clinically unappealing and may be avoided by including intrinsic variability, i.e. serially correlated residual errors. In this paper we extend previous work that investigated optimal designs of population models including serial correlation using stochastic differential equations to optimal design with the more robust, and analytic, AR(1) autocorrelation model. Further, we investigate the importance of correlation strength, design criteria and robust designs. Finally, we explore the optimal design properties when estimating parameters with and without serial correlation. In the investigated examples the designs and estimation performance differs significantly when handling serial correlation.

Mesh:

Year:  2012        PMID: 22415637     DOI: 10.1007/s10928-012-9245-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  16 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

3.  Maximin D-optimal designs for longitudinal mixed effects models.

Authors:  Mario J N M Ouwens; Frans E S Tan; Martijn P F Berger
Journal:  Biometrics       Date:  2002-12       Impact factor: 2.571

4.  POPED, a software for optimal experiment design in population kinetics.

Authors:  Marco Foracchia; Andrew Hooker; Paolo Vicini; Alfredo Ruggeri
Journal:  Comput Methods Programs Biomed       Date:  2004-04       Impact factor: 5.428

5.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

6.  Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

7.  Optimal design for multivariate response pharmacokinetic models.

Authors:  Ivelina Gueorguieva; Leon Aarons; Kayode Ogungbenro; Karin M Jorga; Trudy Rodgers; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-21       Impact factor: 2.745

8.  D-optimal cohort designs for linear mixed-effects models.

Authors:  Fetene B Tekle; Frans E S Tan; Martijn P F Berger
Journal:  Stat Med       Date:  2008-06-30       Impact factor: 2.373

9.  The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.

Authors:  Hanna E Silber; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-14       Impact factor: 2.745

10.  Some general estimation methods for nonlinear mixed-effects models.

Authors:  M Davidian; D M Giltinan
Journal:  J Biopharm Stat       Date:  1993-03       Impact factor: 1.051

View more
  5 in total

1.  The effect of Fisher information matrix approximation methods in population optimal design calculations.

Authors:  Eric A Strömberg; Joakim Nyberg; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-11-01       Impact factor: 2.745

2.  Reduced and optimized trial designs for drugs described by a target mediated drug disposition model.

Authors:  A Brekkan; S Jönsson; M O Karlsson; A C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-06-08       Impact factor: 2.745

3.  Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization.

Authors:  Robert J Bauer; Andrew C Hooker; France Mentre
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-19

4.  Inter occasion variability in individual optimal design.

Authors:  Anders N Kristoffersson; Lena E Friberg; Joakim Nyberg
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-10-01       Impact factor: 2.745

5.  "De-Shrinking" EBEs: The Solution for Bayesian Therapeutic Drug Monitoring.

Authors:  Sarah Baklouti; Peggy Gandia; Didier Concordet
Journal:  Clin Pharmacokinet       Date:  2022-02-04       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.